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Abstract
Introduction: Acute Human Immunodeficiency Virus infection is associated with a range of
neurological conditions. Guillain-Barré syndrome is a rare presentation; acute inflammatory
demyelinating polyneuropathy is the commonest form of Guillain-Barré syndrome. Acute
inflammatory demyelinating polyneuropathy has occasionally been reported in acute
Immunodeficiency Virus infection but little data exists on frequency, management and outcome.
Case presentation: We describe an episode of Guillain-Barré syndrome presenting as acute
inflammatory demyelinating polyneuropathy in a 30-year-old man testing positive for
Immunodeficiency Virus, probably during acute seroconversion. Clinical suspicion was confirmed
by cerebrospinal fluid analysis and nerve conduction studies. Rapid clinical deterioration prompted
intravenous immunoglobulin therapy and early commencement of highly active anti-retroviral
therapy. All symptoms resolved within nine weeks.
Conclusion: Unusual neurological presentations in previously fit patients are an appropriate
indication for Immunodeficiency-Virus testing. Highly active anti-retroviral therapy with adequate
penetration of the central nervous system should be considered as an early intervention, alongside
conventional therapies such as intravenous immunoglobulin.
Introduction
Human Immunodeficiency Virus (HIV) infection is neu-
rotropic and a wide array of neurological presentations
has been described. Alongside common presentations of
meningitis, encephalitis and peripheral neuropathies,
Guillain-Barré syndrome (GBS) has rarely been reported.
Fewer reports exist of the acute inflammatory demyelinat-
ing polyneuropathy (AIDP) variant of GBS presenting as
an acute HIV seroconversion. Little data exists on patient
outcomes or treatment options in HIV-GBS, including
intravenous immunoglobulin (IVIg) and highly active
anti-retroviral therapy (HAART). We discuss the clinical
presentation, outcome and management including the
current evidence base.
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In 2007 a previously well 30-year-old homosexual man
presented with a 5 day history of progressive bilateral
ascending lower limb weakness, preceded by a flu-like ill-
ness lasting for 2 weeks. Examination revealed normal
tone but slightly reduced power at Medical Research
Council (MRC) grading 4/5 [1]. Sensation was intact but
he was areflexic in both legs. Plantar responses were
flexor. The rest of the clinical examination was normal.
Cerebrospinal fluid (CSF) examination showed 26 leuco-
cytes/mm3 (95% lymphocytes), a protein level of 0.72 g/l
(normal range 0.15–0.45 g/l) and a glucose level of 2.3
mmol/l (blood glucose was 5.2 mmol/l). CSF culture and
polymerase chain reaction analyses for herpes simplex
virus, herpes zoster virus, enterovirus, Epstein Barr Virus
and cytomegalovirus (CMV) were negative. The suspected
diagnosis was AIDP, part of the heterogeneous GBS
grouping.
He received supportive management and twice daily
spirometry was undertaken. Although not dyspnoeic, his
FEV1 was reduced at 2.7 l (59% of predicted) and oxygen
therapy was commenced. Transfer to the Intensive Ther-
apy Unit was planned if the FEV1 fell below 1.5 l. After
neurological advice, a 5 day course of daily intravenous
immunoglobulin therapy (IVIg) (0.4 g/kg/day) was com-
menced. Over the next 3 days his condition deteriorated
and by day 4 of IVIg therapy, he had lost all lower limb
power and was developing sensory abnormalities, upper
limb weakness, difficulty swallowing and blunting of
speech.
He had been successfully treated for syphilis in 2005. HIV
antibody testing at that time was negative but, in view of
his established risk factors and new symptoms, a repeat
test was now undertaken and was positive. Screening for
other blood-borne viruses, opportunistic infections and
magnetic resonance imaging of brain and spine were neg-
ative.
On day 5 of IVIg his speech was barely intelligible and left
sided facial nerve palsy developed (Figure 1). Bilateral
upper limb power was significantly reduced to MRC grade
1/5 but respiratory function remained adequate. His HIV
viral load was >100,000 copies/ml and the CD4 count was
408 cells/mm3. He was commenced on highly active
antiretroviral therapy (HAART) with zidovudine, lamivu-
dine and efavirenz. Less than 12 hours later his symptoms
plateaued and a gradual recovery began.
Sensory nerve conduction studies were normal. EMG
motor studies revealed active denervation in distal lower
limb muscles.
Over the next 9 weeks, he received intensive complex
neuro-rehabilitation and at discharge no neurological def-
icits were present, but he continued to experience mild
lower limb neuropathic pain. HAART stopped at 6
months with a CD4 count of 901 cells/mm3. He remains
asymptomatic 7 months after withdrawal of HAART.
Discussion
HIV infection is associated with a range of peripheral neu-
ropathies; distal sensory polyneuropathy, mononeuritis
multiplex, polyradiculopathy, demyelination and drug
toxicities [1]. A specific association with GBS was first sug-
gested in the 1980s. GBS remains uncommon in the gen-
eral population and is a rare presentation of HIV, with
only a small number of case reports in the literature. Ret-
rospective case series from North America and sub-Saha-
ran Africa suggest that GBS is more likely in acute HIV
seroconversion or early infection [1,2]. These patients
may be otherwise asymptomatic so it is vital to consider
HIV testing in all previously well individuals with unusual
neurological presentations. Our patient had a previously
negative HIV test, a high viral load and a robust CD4
count, suggesting acute seroconversion, although this is
impossible to conclusively prove as there are no blood
samples from 2005–2007 to retrospectively test.
Guillain-Barré syndrome has also been described in
advanced HIV. CMV polyradiculopathy can be clinically
indistinguishable at CD4 counts <50 cells/mm [3], lead-
ing some authors to suggest that symptomatic individuals
with advanced immunosuppression should also be
treated presumptively for CMV [3].
Lower motor neurone left sided facial nerve palsy demon-strat d in photographs before (A) and after (B) pati nt a tempts to close eye and mileFigure 1
Lower motor neurone left sided facial nerve palsy demon-
strated in photographs before (A) and after (B) patient 
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represents 75% of cases and classically presents with
ascending symmetrical paresis or paraesthesia, loss of
deep tendon reflexes and autonomic dysfunction. Other
subtypes include a purely motor variant called Acute
Motor Axonal Neuropathy (AMAN), and Fisher's syn-
drome, characterised by acute ophthalmoplegia, ataxia
and areflexia, often in association with lower cranial nerve
palsies. Overlap syndromes combining the above features
occur [4]. Our patient's presentation is typical of AIDP.
Diagnosis is based on clinical features, neurophysiologi-
cal testing and lumbar puncture. The CSF protein level is
raised in 80% of cases. CSF white cells are typically absent
in HIV-negative patients but, as in our case, cells are regu-
larly seen in HIV-GBS [5]. This distinction is not universal
but further highlights the need for HIV testing when unex-
pected CSF findings are seen.
The pathogenesis of HIV-GBS is incompletely understood.
Possible mechanisms include direct HIV neurotoxicity or
autoimmunity. Several features favour an immune mech-
anism. Typical neural histology supports an antibody-
mediated process and high titres of autoantibodies to
myelin sheath glycosphingolipids are found in the serum
of affected patients [3]. The presence of these anti-ganglio-
side antibodies at low CD4 counts suggests that abnormal
immunoregulation in HIV may precipitate a paradoxical
rise in autoantibodies, resulting in GBS.
In the initial stages, neurological weakness is rapidly pro-
gressive, involving respiratory muscles in 25% of cases.
These patients may require mechanical ventilation. After a
disease nadir, usually 2–4 weeks after onset of symptoms
and a variable plateau phase, recovery occurs over a
period of weeks to months. Mortality varies between four
and 15%, and 20% remain disabled at one year despite
treatment. Outcomes in HIV-positive patients are equiva-
lent to those of HIV-negative patients. Early treatment
with plasmapheresis or IVIg therapy have equal efficacy in
reducing the proportion of patients requiring ventilation
during the first four weeks [4].
Since 1996, HAART has revolutionised the treatment of
HIV. Given the proposed role of autoimmunity in HIV-
GBS, it seems likely that antiretroviral drugs will alter the
course of neurological illness. Individual case reports of
patients on pre-established HAART describe GBS as a drug
side effect [6] or an immune reconstitution syndrome [7]
but there are only five previously published cases of
antiretroviral-naïve individuals presenting with HIV-GBS
who received HAART as a component of acute manage-
ment (Table 1) [8-11].
Three antiretroviral-naïve HIV-GBS patients presented
with low CD4 counts (<200 cells/mm3) and made a good
recovery with long term HAART. Two others, like our case,
began therapy at higher CD4 counts and improved. Our
patient's apparent treatment response was unusually
rapid, raising the possibility that HAART initiation was
coincidental with onset of natural recovery but when
viewed alongside the other cases it does seem that early
introduction of antiretroviral treatment is beneficial, par-
ticularly if symptoms are severe and progressive.
Both previous cases of HIV-GBS at high CD4 counts
encountered transient neurological relapses when HAART
was stopped. Recurrent GBS or Chronic Inflammatory
Demyelinating Polyneuropathy affects 3% of HIV nega-
tive patients [4], but has not been described with HIV. The
duration of therapy at high CD4 counts and risk of relapse
needs further study.
Finally, the choice of antiretroviral drug combination
requires consideration. Eight drugs from three different
antiretroviral classes were used in the five previous cases.
The best combination is unclear. As HIV is a neurotropic
virus and the nervous system is a sanctuary site for infec-
tion, drugs which effectively cross the blood-brain barrier
are most appropriate. The nucleoside reverse transcriptase
inhibitors zidovudine, lamivudine and abacavir, and non-
nucleoside reverse transcriptase inhibitors efavirenz and
nevirapine penetrate the central nervous system well but
protease inhibitors are less reliable. This explains our
choice of zidovudine, lamivudine and efavirenz. Nevirap-
ine was avoided as the risk of adverse events with this drug
increases at higher CD4 counts.
Conclusion
The AIDP variant of GBS is a rare presentation of acute
HIV seroconversion, with significant mortality and mor-
bidity. Early neurological diagnosis and consideration of
HIV testing are important to improve outcome. Although
data are sparse, it appears reasonable to consider early
commencement of HAART using drugs with good CNS
penetration, particularly if there is continued deteriora-
tion on conventional therapy. This case adds to the lim-
ited literature on this topic and highlights the need for
further study.
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